Pyxis Oncology
- Founded: 2019
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: NSCLC, Breast Cancer
- Drug types: ONC
- Lead product: PYX-201
- Product link: https://pyxisoncology.com/portfolio/#pipeline
- Funding: $168M IPO Oct 2021; $152M B Mar 2021; $22M A Jul 2019
- Investors: Leaps by Bayer, Agent Capital, Ipsen, Longwood Fund
pyxisoncology.com linkedin.com job board
Short description:
Antibody Immunotherapy
Drug notes:
PYX-106 Clin0 cancers; 3 add'l programs tumors
Long description:
Pyxis Oncology is developing therapies for difficult-to-treat cancers. To tackle cancer, Pyxis is pursuing both antibody-drug conjugates (ADCs) and monoclonal antibodies (mAb) to build an arsenal of next-generation therapeutics. ADCs work by targeting tumors and releasing cytotoxic payloads, while mAbs work to modulate immune regulatory mechanisms to serve as immunotherapies.. Pyxis has assembled a portfolio of clinical assets for both these classes. This includes their ADC, PYX-201, an ADC in Phase 1 clinical trials in patients with relapsed or refractory solid tumors.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com